News:

OrPro Therapeutics and Collaborators Present Key Theradux™ Data

– Demonstrates Restoration of Mucus Transportability – SAN DIEGO, October 28, 2016 — OrPro Therapeutics, Inc., and its research collaborators at the University of Alabama at Birmingham (UAB) today presented promising new non-clinical human subject data on the efficacy of OrPro’s inhaled mucus-normalizing drug Theradux™ (modified human thioredoxin-1) during a poster session at the North […]

Download
Read More →

OrPro Therapeutics Receives US Patent Covering Novel Enzymatic Treatment for Cystic Fibrosis

– Broad claims extend protection to 2034 – – In vivo safety and mechanism-based proof-of-concept data presented at key conferences – SAN DIEGO, October 27, 2015 — OrPro Therapeutics, Inc. announced today that the US Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,168,290 covering the ability of Theradux™ (recombinant modified human thioredoxin-1) […]

Download
Read More →

OrPro Therapeutics Presents Data for Lead Compound at Annual North American Cystic Fibrosis Conference

SAN DIEGO, Oct. 9, 2014 /PRNewswire/ — OrPro Therapeutics, Inc., a pre-clinical stage biopharmaceutical company, announced that it will present data on the development of its inhaled treatment for cystic fibrosis (CF) at the 28thAnnual North American Cystic Fibrosis Conference, October 9 – 11 in Atlanta. CF is an inherited genetic disease that affects approximately 80,000 people worldwide. OrPro’s lead compound, […]

Read More →

OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis

July 31, 2012, SAN DIEGO -­‐-­‐ OrPro Therapeutics Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant enables OrPro to advance development of its lead product, ORP-­‐ 100, for the treatment of cystic […]

Download
Read More →